Rivaroxaban 2.5 mg Tablet PCD Franchise in Mumbai

Anti-Coagulant Medicine Supplier in Delhi

Cardiovascular Tablet Distributor in Chennai

Thrombosis Prevention Pharma Franchise in Pune

Rivaroxaban Tablet Stockist in Kolkata
Anti-Coagulant Therapy Tablet Export & Manufacturing in Hyderabad

Home/Products /rivaroxaban-micronized-2-5mg-tablet

Rivafoli 2.5 tablet

Composition : Rivaroxaban (2.5mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Rivafoli 2.5 Tablet contains Rivaroxaban 2.5 mg, a direct oral anticoagulant (DOAC) that helps prevent blood clot formation and reduce the risk of stroke in patients with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE).

Belonging to the cardiology and anti-coagulant segment, Rivaroxaban is widely prescribed for both prophylaxis and treatment of thromboembolic events. Its oral administration provides convenience and adherence compared to traditional injectable anticoagulants.

The medicine works by selectively inhibiting Factor Xa, which prevents the conversion of prothrombin to thrombin, thereby reducing clot formation and maintaining normal blood flow. This mechanism is vital for cardiovascular patients at risk of recurrent events.

For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Rivafoli 2.5 Tablet offers a profitable B2B opportunity, catering to hospitals, cardiology clinics, and specialty pharmacies across India. Its therapeutic importance ensures consistent demand and high market value.

Read More

About the Product

Rivafoli 2.5 Tablet contains Rivaroxaban 2.5 mg, a direct oral anticoagulant (DOAC) that helps prevent blood clot formation and reduce the risk of stroke in patients with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE).

Belonging to the cardiology and anti-coagulant segment, Rivaroxaban is widely prescribed for both prophylaxis and treatment of thromboembolic events. Its oral administration provides convenience and adherence compared to traditional injectable anticoagulants.

The medicine works by selectively inhibiting Factor Xa, which prevents the conversion of prothrombin to thrombin, thereby reducing clot formation and maintaining normal blood flow. This mechanism is vital for cardiovascular patients at risk of recurrent events.

For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Rivafoli 2.5 Tablet offers a profitable B2B opportunity, catering to hospitals, cardiology clinics, and specialty pharmacies across India. Its therapeutic importance ensures consistent demand and high market value.

Common side effects include bleeding, bruising, or minor nosebleeds. Rare but serious effects may include gastrointestinal bleeding, intracranial hemorrhage, or severe allergic reactions. Seek immediate medical attention if you experience prolonged bleeding, black stools, or severe dizziness.

Rivafoli 2.5 Tablet is indicated for the prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). It may also be prescribed alongside low-dose aspirin to reduce the risk of heart attack, stroke, or blood clots.

Take Rivafoli 2.5 Tablet exactly as prescribed, preferably at the same time each day. Do not stop or change the dose without consulting your doctor, as this increases the risk of blood clots. Inform your physician if you have kidney or liver disease, a history of bleeding disorders, or are on other blood-thinning medications.

Store Rivafoli 2.5 Tablet in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation